Literature DB >> 16646565

Epstein-Barr virus-associated Hodgkin's disease following renal transplantation.

Jung-Hye Choi1, Myung-Ju Ahn, Young-Ha Oh, Sang-Woong Han, Ho-Jung Kim, Young-Yeul Lee, In-Soon Kim.   

Abstract

Post-transplant lymphoproliferative disorders (PTLD) have been recognized as a complication of immunosuppression and occur with a reported incidence of 1 to 8% of recipients receiving solid organ transplantation. PTLD are classified into two major categories, polymorphic and monomorphic PTLD. The majority of the monomorphic PTLD cases are non-Hodgkin's lymphoma of B-cell origin. Hodgkin's disease is not part of the typical spectrum of PTLD; however, it has been rarely reported. We describe a case of Hodgkin's disease following renal transplantation. A 41-year-old man developed right cervical lymphadenopathy following renal transplantation 116 months previously for chronic renal failure of unknown origin. He had been taking cyclosporine, mycophenolate mofetil and prednisone. A lymph node biopsy revealed mixed cellularity Hodgkin's disease. Immunohistochemical staining was positive for CD30 and EBV-latent membrane protein-1. No other site of disease was identified. The immunosuppressive agents were reduced (mycophenolate mofetil was discontinued, cyclosporine dose reduced from 200 mg to 150 mg and prednisone continued at 5 mg). After 2 cycles of ABVD followed by radiation therapy (3600 cGy), he achieved complete remission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646565      PMCID: PMC3891064          DOI: 10.3904/kjim.2006.21.1.46

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  18 in total

Review 1.  Epstein-Barr virus-recent advances.

Authors:  Karen F Macsween; Dorothy H Crawford
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

2.  Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease.

Authors:  P-T T Pham; A H Wilkinson; H A Gritsch; P C T Pham; J M Miller; C R Lassman; G M Danovitch
Journal:  Transplant Proc       Date:  2002-06       Impact factor: 1.066

3.  Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy.

Authors:  I A Darenkov; M A Marcarelli; G P Basadonna; A L Friedman; K M Lorber; J G Howe; J Crouch; M J Bia; A S Kliger; M I Lorber
Journal:  Transplantation       Date:  1997-09-27       Impact factor: 4.939

Review 4.  Cancers in renal transplant recipients.

Authors:  I Penn
Journal:  Adv Ren Replace Ther       Date:  2000-04

Review 5.  Epstein-Barr virus and post-transplant lymphoproliferative disease.

Authors:  R D Holmes; R J Sokol
Journal:  Pediatr Transplant       Date:  2002-12

6.  Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease.

Authors:  A Savoie; C Perpête; L Carpentier; J Joncas; C Alfieri
Journal:  Blood       Date:  1994-05-01       Impact factor: 22.113

7.  Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.

Authors:  Vikas R Dharnidharka; Vonda K Douglas; Stephen P Hunger; Robert S Fennell
Journal:  Pediatr Transplant       Date:  2004-02

8.  Posttransplant lymphoproliferative disease: treatment and outcome in renal transplant recipients.

Authors:  M J Soler; J M Puig; M Mir; J Parrilla; C Pedro; A Salar; S Serrano; J Lloveras
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

9.  Neoplastic complications of transplantation.

Authors:  I Penn
Journal:  Semin Respir Infect       Date:  1993-09

Review 10.  The post-transplant lymphoproliferative disorder-a literature review.

Authors:  Rokshana Shroff; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2004-02-21       Impact factor: 3.714

View more
  5 in total

1.  Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies.

Authors:  Lesley A Anderson; Shahinaz Gadalla; Lindsay M Morton; Ola Landgren; Ruth Pfeiffer; Joan L Warren; Sonja I Berndt; Winnie Ricker; Ruth Parsons; Eric A Engels
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

2.  Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.

Authors:  Aaron S Rosenberg; Andreas K Klein; Robin Ruthazer; Andrew M Evens
Journal:  Am J Hematol       Date:  2016-04-26       Impact factor: 10.047

3.  Classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder in a kidney transplant recipient: a diagnostic pitfall.

Authors:  Taro Mohri; Yoshihiro Ikura; Asako Hirakoso; Masashi Okamoto; Masakatsu Hishizawa; Akifumi Takaori-Kondo; Seiichi Kato; Shigeo Nakamura; Kai Yoshimura; Hidetoshi Okabe; Yasuhiro Iwai
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

4.  Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: A United Kingdom nationwide case-control study.

Authors:  Meena Rafiq; Andrew Hayward; Charlotte Warren-Gash; Spiros Denaxas; Arturo Gonzalez-Izquierdo; Georgios Lyratzopoulos; Sara Thomas
Journal:  J Allergy Clin Immunol       Date:  2019-11-12       Impact factor: 10.793

5.  Retinochoroidal toxoplasmosis in a patient with cerebral post-transplant lymphoproliferative disease of Hodgkin's type: a diagnostic challenge.

Authors:  Ruchi Mittal; Gabrielle Thumann; George Souteyrand; David Kuerten; Sarah E Coupland
Journal:  J Ophthalmic Inflamm Infect       Date:  2015-08-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.